Weekly Digest – April 2026 Weekly Digest – April 2026 10 April 2026: Disitamab Vedotin approved in china as first line therapy for HER2 expressing urothelial carcinoma RemeGen has received approval in China for disitamab vedotin (RC48, Aidixi) in combination […]
Weekly Digest – April 2026 Weekly Digest – April 2026 13 April 2026: Ifinatamab Deruxtecan receives U.S. Priority Review for previously treated extensive-stage SCLC progressing after platinum-based chemotherapy Daiichi Sankyo and Merck have received U.S. FDA acceptance and Priority Review […]
Weekly Digest – April 2026 Weekly Digest – April 2026 14 April 2026: GlycoNex receives PMDA approval in Japan to initiate first-in-human phase 1 trial of GNX1021 in gastrointestinal cancers GlycoNex, Inc. has received approval from Japan’s Pharmaceuticals and Medical […]
Weekly Digest – April 2026 Weekly Digest – April 2026 15 April 2026: CSPC Pharmaceutical Group Limited obtains NMPA clinical trial approval for TF-targeted ADC SYS6051 in China CSPC Pharmaceutical Group Limited has received clinical trial approval in China for […]
Weekly Digest – April 2026 Weekly Digest – April 2026 14 April 2026: CrossBridge Bio enters an agreement to be acquired by Eli Lilly to advance next-generation dual-payload ADCs CrossBridge Bio, Inc. has entered into a definitive agreement to be […]
Weekly Digest – April 2026 Weekly Digest – April 2026 10 April 2026: 3B Pharmaceuticals and TetraKit Technologies announce strategic collaboration for joint radioligand therapy (RLT) development 3B Pharmaceuticals GmbH and TetraKit Technologies have entered into a strategic collaboration to […]
